Relmada Therapeutics annual cash and equivalents
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Relmada Therapeutics Cash & Equivalents Growth & History (RLMD)
Relmada Therapeutics's cash and equivalents was $3.5M for fiscal 2025.
View full Relmada Therapeutics company overviewRelmada Therapeutics annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.5M | −$360,486 | −9.35% |
| 2024 | 2024-12-31 | $3.9M | −$234,542 | −5.73% |
| 2023 | 2023-12-31 | $4.1M | −$1.3M | −24.17% |
| 2022 | 2022-12-31 | $5.4M | −$39.0M | −87.86% |
| 2021 | 2021-12-31 | $44.4M | $41.9M | +1681.02% |
| 2020 | 2020-12-31 | $2.5M | −$33.8M | −93.12% |
| 2019 · Dec 31 | 2019-12-31 | $36.3M | — | — |
| 2019 · Jun 30 | 2019-06-30 | $9.2M | $7.0M | +311.65% |
| 2018 | 2018-06-30 | $2.2M | $528,431 | +30.89% |
| 2017 | 2017-06-30 | $1.7M | −$6.8M | −79.88% |
| 2016 | 2016-06-30 | $8.5M | −$14.0M | −62.17% |
| 2015 | 2015-06-30 | $22.5M | −$3.1M | −12.10% |
| 2014 | 2014-06-30 | $25.6M | — | — |
| 2013 · Dec 31 | 2013-12-31 | $3.5M | $1.7M | +98.69% |
| 2013 · Aug 31 | 2013-08-31 | $15,290 | $6,341 | +70.86% |
| 2012 · Dec 31 | 2012-12-31 | $1.8M | — | — |
| 2012 · Aug 31 | 2012-08-31 | $8,949 | — | — |
Relmada Therapeutics quarterly cash and equivalents
Q4.12
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q4.13
Q1.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.3M | $10.0M | +737.50% |
| Q1 2026 | 2026-03-31 | $9.8M | $8.6M | +750.34% |
| Q4 2025 | 2025-12-31 | $3.5M | −$360,486 | −9.35% |
| Q3 2025 | 2025-09-30 | $1.4M | −$99,305 | −6.69% |
| Q2 2025 | 2025-06-30 | $1.4M | −$732,909 | −35.13% |
| Q1 2025 | 2025-03-31 | $1.1M | −$185,312 | −13.88% |
| Q4 2024 | 2024-12-31 | $3.9M | −$234,542 | −5.73% |
| Q3 2024 | 2024-09-30 | $1.5M | −$5.2M | −77.85% |
| Q2 2024 | 2024-06-30 | $2.1M | −$12.4M | −85.58% |
| Q1 2024 | 2024-03-31 | $1.3M | −$27.6M | −95.38% |
| Q4 2023 | 2023-12-31 | $4.1M | −$1.3M | −24.17% |
| Q3 2023 | 2023-09-30 | $6.7M | −$35.8M | −84.25% |
| Q2 2023 | 2023-06-30 | $14.5M | −$22.8M | −61.17% |
| Q1 2023 | 2023-03-31 | $28.9M | −$16.0M | −35.70% |
| Q4 2022 | 2022-12-31 | $5.4M | −$39.0M | −87.86% |
| Q3 2022 | 2022-09-30 | $42.5M | $31.1M | +271.41% |
| Q2 2022 | 2022-06-30 | $37.3M | $32.6M | +697.99% |
| Q1 2022 | 2022-03-31 | $44.9M | $41.1M | +1081.23% |
| Q4 2021 | 2021-12-31 | $44.4M | $41.9M | +1681.02% |
| Q3 2021 | 2021-09-30 | $11.4M | $3.9M | +51.75% |
| Q2 2021 | 2021-06-30 | $4.7M | −$9.2M | −66.22% |
| Q1 2021 | 2021-03-31 | $3.8M | −$8.4M | −68.89% |
| Q4 2020 | 2020-12-31 | $2.5M | −$33.8M | −93.12% |
| Q3 2020 | 2020-09-30 | $7.5M | −$305,145 | −3.89% |
| Q2 2020 | 2020-06-30 | $13.8M | $4.6M | +49.99% |
| Q1 2020 · Mar 31 | 2020-03-31 | $12.2M | $10.2M | +495.30% |
| Q4 2019 · Dec 31 | 2019-12-31 | $36.3M | $33.9M | +1394.94% |
| Q1 2020 · Sep 30 | 2019-09-30 | $7.8M | $7.0M | +784.50% |
| Q4 2019 · Jun 30 | 2019-06-30 | $9.2M | $7.0M | +311.65% |
| Q3 2019 | 2019-03-31 | $2.1M | −$2.2M | −51.76% |
| Q2 2019 | 2018-12-31 | $2.4M | −$3.5M | −59.14% |
| Q1 2019 | 2018-09-30 | $887,494 | −$3.8M | −81.05% |
| Q4 2018 | 2018-06-30 | $2.2M | $528,431 | +30.89% |
| Q3 2018 | 2018-03-31 | $4.3M | $1.5M | +54.45% |
| Q2 2018 | 2017-12-31 | $5.9M | $1.2M | +25.99% |
| Q1 2018 | 2017-09-30 | $4.7M | −$1.5M | −24.71% |
| Q4 2017 | 2017-06-30 | $1.7M | −$6.8M | −79.88% |
| Q3 2017 | 2017-03-31 | $2.8M | −$8.6M | −75.71% |
| Q2 2017 | 2016-12-31 | $4.7M | −$10.4M | −68.84% |
| Q1 2017 | 2016-09-30 | $6.2M | −$12.9M | −67.54% |
| Q4 2016 | 2016-06-30 | $8.5M | −$14.0M | −62.17% |
| Q3 2016 | 2016-03-31 | $11.3M | −$15.6M | −57.90% |
| Q2 2016 | 2015-12-31 | $15.1M | −$16.3M | −51.85% |
| Q1 2016 | 2015-09-30 | $19.2M | −$8.2M | −30.03% |
| Q4 2015 | 2015-06-30 | $22.5M | −$3.1M | −12.10% |
| Q3 2015 | 2015-03-31 | $27.0M | — | — |
| Q2 2015 | 2014-12-31 | $31.4M | $27.9M | +791.97% |
| Q1 2015 | 2014-09-30 | $27.4M | — | — |
| Q4 2014 | 2014-06-30 | $25.6M | — | — |
| Q1 2014 · Feb 28 | 2014-02-28 | $2,626 | −$4,878 | −65.01% |
| Q4 2013 · Dec 31 | 2013-12-31 | $3.5M | $1.7M | +98.69% |
| Q1 2014 · Nov 30 | 2013-11-30 | $6,166 | — | — |
| Q4 2013 · Aug 31 | 2013-08-31 | $15,290 | $6,341 | +70.86% |
| Q2 2013 | 2013-05-31 | $664 | — | — |
| Q1 2013 | 2013-02-28 | $7,504 | — | — |
| Q4 2012 | 2012-12-31 | $1.8M | — | — |
| Q4 2012 | 2012-08-31 | $8,949 | — | — |
Relmada Therapeutics cash and equivalents trends
Over the last five fiscal years, Relmada Therapeutics's cash and equivalents increased from $2.5M to $3.5M, a change of $1.0M. The latest reported quarter, Q2 2026, shows $11.3M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relmada Therapeutics source filings ↗